General Anesthesia, Immune Function, Regional Anesthesia
Conditions
Keywords
anesthesia, general anesthesia, neuraxial anesthesia, monocyte funtion, CD 14, HLA-DR, Interleukines
Brief summary
The impact of different anesthetic techniques on the immune system remains unclear. Aim of this ex vivo / in vitro study was to determine the effects of general and neuraxial anesthesia on monocyte subset alteration and the release of prototypical pro- and anti-inflammatory cytokines. Twenty patients undergoing total knee replacement surgery were randomly assigned to receive either general anesthesia (ITN) or combined spinal/epidural anesthesia (CSE). CD14 and HLA-DR expression patterns on monocytes and intracellular TNF-alpha production were quantified via flow cytometry. TNF-α and IL-10 release were measured via enzyme linked immunosorbent assay (ELISA).
Detailed description
Numerous of factors affect the immunological response during surgery. Despite intensive research, the impact of different anesthetic techniques on the immune system remains unclear. Aim of this ex vivo / in vitro study was to determine the effects of general and neuraxial anesthesia on monocyte subset alteration and the release of prototypical pro- and anti-inflammatory cytokines. Twenty patients undergoing total knee replacement surgery were randomly assigned to receive either general anesthesia (ITN) or combined spinal/epidural anesthesia (CSE). Samples of venous blood were taken from the patients before and after induction of anesthesia, immediately, 6 hours, 24 hours, and 48 hours after surgery. All blood samples were incubated in presence or absence of LPS (lipopolysaccharide; 1 µg/ml) for 24 hours. CD14 and HLA-DR expression patterns on monocytes and intracellular TNF-alpha production were quantified via flow cytometry. TNF-α and IL-10 release were measured via enzyme linked immunosorbent assay (ELISA).
Interventions
None listed
Sponsors
Study design
Eligibility
Inclusion criteria
* Total knee replacement surgery * 18 years or older
Exclusion criteria
* clinical signs of infection, * neoplasia * treatment with immunomodulatory agents * any kind of immune mediated disease.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| CD 14 and HLA-DR Expression Patterns on monocytes | 1 year | CD 14 and HLA-DR Expression Patterns on monocytes in whole blood culture assay |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Intracellular TNF-alpha production | 1 year | Intracellular TNF-alpha production in whole blood culture assay |
| TNF-alpha and IL-10 release | 1 year | TNF-alpha and IL-10 release in whole blood culture assay |
Countries
Germany